Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP1 | O94782 | 1/20 | 0.43 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | IKBKB | O14920 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4549141 | 0.91 | DRD2 (0.45) | USP1WDR48DRD2DRD3HTR2A | |
| SCHEMBL8433245 | 0.86 | DRD2 (0.49) | DRD2DRD3HTR2AHTR2CKCNH2 | |
| SCHEMBL16956096 | 0.79 | GABRA1 (0.45) | HTR2CSLC6A2 | |
| SCHEMBL19171079 | 0.77 | HTR2A (0.43) | USP1WDR48HTR2AHTR2CSLC6A2 | |
| SCHEMBL19171106 | 0.77 | HTR2A (0.43) | USP1WDR48HTR2AHTR2CSLC6A2 | |
| SCHEMBL18672671 | 0.77 | HTR2A (0.43) | USP1WDR48HTR2AHTR2CSLC6A2 | |
| SCHEMBL20252415 | 0.77 | L3MBTL1 (0.49) | USP1WDR48DRD2DRD3HTR2A | |
| SCHEMBL22132285 | 0.72 | HTR2C (0.65) | DRD2DRD3HTR2AHTR2CIKBKB | |
| SCHEMBL9310414 | 0.72 | HTR2C (0.65) | DRD2DRD3HTR2AHTR2CIKBKB | |
| SCHEMBL17308285 | 0.71 | KEAP1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367712-B2 | Substituted amide beta secretase inhibitors | Merck, Sharp & Dohme, Corp. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120232064-A1 | ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2012-09-13 | — | — | US | disclosed |
| US-7868000-B2 | Aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2011-01-11 | — | — | US | disclosed |
| US-20110003825-A1 | SUBSTITUTED AMIDE BETA SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2011-01-06 | — | — | US | disclosed |
| US-7812013-B2 | Macrocyclic heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2010-10-12 | — | — | US | disclosed |
| US-7803802-B2 | Substituted amide beta secretase inhibitors | SCHERING CORPORATION (US) | 2010-09-28 | — | — | US | disclosed |
| US-7759354-B2 | Bicyclic guanidine derivatives as asparyl protease inhibitors, compositions, and uses thereof | SCHERING CORPORATION (US) | 2010-07-20 | — | — | US | disclosed |
| US-20070060575-A1 | Aspartyl protease inhibitors | MERCK SHARP & DOHME LLC | 2007-03-15 | — | — | US | disclosed |
| US-20060281729-A1 | Macrocyclic heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232064-A1 | ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, BACE1 | USP1 266/4885WDR48 2811/4885DRD2 1342/4885 |
| US-20070060575-A1 | Aspartyl protease inhibitors | CHRM2, BACE1, CHRM1 | USP1 438/4885WDR48 2265/4885DRD2 1459/4885 |
| US-20060281729-A1 | Macrocyclic heterocyclic aspartyl protease inhibitors | CHRM1, CHRM2, CHRM5 | USP1 398/4885WDR48 2752/4885DRD2 748/4885 |
| US-20110003825-A1 | SUBSTITUTED AMIDE BETA SECRETASE INHIBITORS | BACE1, BACE2, SRR | USP1 2874/4885WDR48 2965/4885DRD2 2849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.